Equity Profile

ORKA

Oruka Therapeutics, Inc.

Health CareBiotechnology$7.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various health conditions. As part of the health care sector, it plays a crucial role in advancing medical treatments and improving patient outcomes.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In Q1 2026, Oruka reported an EPS of -$0.48, which was better than the expected -$0.52, resulting in an 8.4% surprise. However, the stock fell 2.27% the next day, indicating market skepticism despite the positive EPS surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Oruka's upcoming earnings are mixed, with investors hoping for continued improvement in EPS and revenue. The company has consistently beaten EPS estimates in the past, but the stock reaction has been volatile.

Bull Case

The optimistic view is that Oruka will continue its trend of beating EPS estimates, potentially leading to a significant stock price increase if revenue growth is also strong.

Bear Case

On the pessimistic side, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in determining if the company can maintain its track record of beating estimates, which could influence investor sentiment.

How is revenue growth trending compared to previous quarters?

Understanding revenue growth is essential for assessing the company's market position and future prospects, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's ability to maintain its EPS beat trend, as the company has consistently surprised positively in the past despite market volatility.

Supporting Evidence

Oruka has a 100% EPS beat rate in the last four quarters, indicating strong operational performance.

The options market is pricing in a significant move, suggesting traders expect volatility that could favor a positive outcome.

Key Risk

If EPS comes in below -$0.55, it could undermine confidence in the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Oruka can sustain its positive EPS surprises and show meaningful revenue growth.

Bull Confirmed If

An EPS of -$0.45 or better would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$0.55 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect high volatility around the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +3.2% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests the stock could rise by around 2.49% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a potential drop of around 2.31%, indicating disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug development timelines and their potential impact on revenue.
2Insights into market demand for Oruka's products and how it compares to competitors.
3Management's outlook on future earnings and revenue growth for the next quarter.
4Details on cost management strategies and their effect on profitability.
5Any commentary on regulatory developments that could impact product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view is that Oruka will continue its trend of beating EPS estimates, potentially leading to a significant stock price increase if revenue growth is also strong.

Bear Case

On the pessimistic side, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in determining if the company can maintain its track record of beating estimates, which could influence investor sentiment.

How is revenue growth trending compared to previous quarters?

Understanding revenue growth is essential for assessing the company's market position and future prospects, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's ability to maintain its EPS beat trend, as the company has consistently surprised positively in the past despite market volatility.

Supporting Evidence

Oruka has a 100% EPS beat rate in the last four quarters, indicating strong operational performance.

The options market is pricing in a significant move, suggesting traders expect volatility that could favor a positive outcome.

Key Risk

If EPS comes in below -$0.55, it could undermine confidence in the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Oruka can sustain its positive EPS surprises and show meaningful revenue growth.

Bull Confirmed If

An EPS of -$0.45 or better would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$0.55 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect high volatility around the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests the stock could rise by around 2.49% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a potential drop of around 2.31%, indicating disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug development timelines and their potential impact on revenue.
2Insights into market demand for Oruka's products and how it compares to competitors.
3Management's outlook on future earnings and revenue growth for the next quarter.
4Details on cost management strategies and their effect on profitability.
5Any commentary on regulatory developments that could impact product approvals.